Demand Analysis for GLP-1 Nutritional Support Market in China The China market rose from approximately 10.8% in 2020 to 2024 to 15.4% during 2025 to 2035, fueled by government-led metabolic health programs and expansion in GLP-1 drug coverage
These localized reactions often stem from the injection technique, needle sensitivity, or mild inflammatory response at the injection site and do not necessarily indicate an allergy to the medication itself
The experimental drug has shown particular promise as a treatment for obesity
In addition, exenatide was shown to activate GLP-1R and inhibit the PI3K/AKT pathway to inhibit the growth, migration, and invasion of ovarian cancer cells, and promote cell apoptosis, thereby producing anticancer effects on diabetic patients with ovarian cancer (218)
Sebnem Kalemli-Ozcan et al., Mortality decline, human capital investment, and economic growth, Journal of Development Economics (June 2000), 123